-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On April 20, Guangzhou Xiangxue Pharmaceutical announced that its grandson company Xiangxue Life Sciences TCR-T therapeutic product TAEST1901 injection was approved for clinical use
In recent years, T cell receptor biopharmaceuticals have received high attention in the industry.
TAEST1901 injection is the second TCR-T product approved for clinical trials since Xiangxue Life Sciences obtained the IND approval for the first TCR-T product (TAEST16001 injection) in China in March 2019
TAEST1901 injection is a HLA-A*02:01/AFP specific affinity-enhanced TCR-T therapeutic product, targeting the complex composed of HLA-A*02:01 and AFP antigenic peptides.
Through systematic preclinical studies, TAEST1901 injection showed good safety